Microbot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial
08. Juli 2024 08:20 ET
|
Microbot Medical Inc.
The first clinical case was performed at Brigham and Women’s Hospital The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY® Endovascular...
Microbot Medical Partners with Baptist Hospital of Miami to Participate in its Pivotal Human Clinical Trial
03. Juli 2024 08:20 ET
|
Microbot Medical Inc.
BRAINTREE, Mass., July 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces it has received...
Microbot Medical Partners with Brigham and Women's Hospital for Its Pivotal Human Clinical Trial
20. Juni 2024 08:25 ET
|
Microbot Medical Inc.
Following FDA Approval to Commence the Clinical Trial, an Official Site Initiation Has Taken Place as Preparation for Patient Enrollment Advances Multiple Robotic Systems Already Received by the Site...
Microbot Medical Announces Brigham and Women's Hospital as a Site for its Pivotal Human Clinical Trial
17. Juni 2024 08:30 ET
|
Microbot Medical Inc.
BRAINTREE, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announces that Brigham and Women’s Hospital (BWH), a leading academic medical center located in Boston,...
Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
04. Juni 2024 16:20 ET
|
Microbot Medical Inc.
HINGHAM, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering priced at-the-market...
Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
03. Juni 2024 12:11 ET
|
Microbot Medical Inc.
HINGHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 1,566,669 shares of...
Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial
03. Juni 2024 08:20 ET
|
Microbot Medical Inc.
BRAINTREE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces that it has...
Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™
29. April 2024 08:30 ET
|
Microbot Medical Inc.
BRAINTREE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today reports that the first...
Microbot Medical Shares Status Following Recent Geopolitical Events
15. April 2024 08:30 ET
|
Microbot Medical Inc.
All Regulatory, Clinical, Operational and Pre-Commercial Activities Continue to Stay on Track Despite the On-going Situation in Israel Company Believes that Both Regulatory and Commercial...
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US
05. Februar 2024 07:30 ET
|
Microbot Medical Inc.
BRAINTREE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the LIBERTY® Endovascular Robotic Surgical System, announced that it has filed an...